Information Provided By:
Fly News Breaks for March 24, 2017
CBAY
Mar 24, 2017 | 08:36 EDT
Roth Capital analyst Sa'ar Yaniv notes that CymaBay expects that data from two arms of the ongoing, second Phase 2 study of seladelpar in primary biliary cholangitis will be released in Q3, and data from the third arm will be available by YE17. The analyst believes that shares continue to trade up in front of the data, and with recent pull back, the current price represents an "attractive entry point." He reiterates a Buy rating and $6 price target on the shares.
News For CBAY From the Last 2 Days
There are no results for your query CBAY